Phase I Evaluation of Alpha-Type-1 DC-Based and cDC-Based Intralymphatic Vaccines in Patients With Metastatic Melanoma.
Latest Information Update: 18 Sep 2021
At a glance
- Drugs Melanoma vaccine (Primary)
- Indications Malignant melanoma
- Focus Adverse reactions
- 26 Sep 2017 Biomarkers information updated
- 15 Oct 2013 Planned end date changed from 1 May 2012 to 1 Dec 2013 as reported by ClinicalTrials.gov.
- 15 Oct 2013 Status changed from completed to active, no longer recruiting as reported by ClinicalTrials.gov.